A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Clinical trial NCT05435339 · TERMINATED

Trial details

NCT number: NCT05435339
Sponsor: Genmab
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2022-10-04
Primary completion: 2024-05-24
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.